Brain imaging in MSA revealed that distinct cerebellar and medullary atrophy patterns were closely linked to cardiovascular ...

U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to ...

The data indicate it’s worth a shot to try TEER in many with secondary MR, but clinical judgement is critical.

Here’s a quick refresher: the systolic pressure (the top number) is the force of your blood when your heart is actively ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous ...

A racing or forceful heartbeat at rest indicates heightened sympathetic tone, a hallmark of rising blood pressure. Wearable fitness trackers have revealed that individuals whose resting pulse averages ...

Windtree has previously reported two positive early cardiogenic shock Phase 2 studies in SCAI Stage B patients The SEISMiC C interim analysis will provide a preliminary assessment of istaroxime safety ...

Heart failure (HF) is a growing global health concern, affecting more than 64 million people worldwide. It develops when the heart can no longer pump enough blood to meet the body's demands, often due ...

Heart attack survival odds have dramatically improved over the past 5 decades, but more people are dying from chronic cardiac ...

Thanks to medical advancements, heart attack deaths have dropped nearly 90% in the last 50 years. But deaths from these ...

From 1970 to 2022, there was a decrease in heart disease mortality overall, but an increase in mortality from other heart ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...